复方海蛇胶囊联合石杉碱甲治疗阿尔茨海默病的临床研究

Clinical study on Compound Haishe Capsules combined with huperzine A in treatment of Alzheimer’s disease

目的研究复方海蛇胶囊联合石杉碱甲片治疗阿尔茨海默病的临床疗效。方法选取2016年1月-2019年1月文昌市人民医院收治的126例阿尔茨海默病患者为研究对象,将所有患者采用随机数字表法分为对照组和治疗组,每组各63例。对照组患者口服石杉碱甲片,2片/次,2次/d;治疗组患者在对照组治疗的基础上口服复方海蛇胶囊,3粒/次,3次/d。两组患者连续治疗6个月。观察两组的临床疗效,比较两组的日常生活能力量表(ADL)评分、简易智力状态检查量表(MMSE)评分、临床痴呆程度评定量表(CDR)评分,基底动脉(BA)、双侧大脑中动脉(MCA)的平均血流速度(MFV)和搏动指数(PI)以及血清炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为79.37%、93.65%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者MMSE评分和ADL评分均显著升高,CDR评分显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组患者MMSE评分、ADL评分和CDR评分明显优于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者BA、MCA的MFV均显著升高,PI显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组患者BA、MCA的MFV和PI明显优于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者白细胞介素-6(IL-6)、超敏C-反应蛋白(hs-CRP)和丙二醛(MDA)水平均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组患者血清炎性因子水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论复方海蛇胶囊联合石杉碱甲片治疗阿尔茨海默病具有较好的临床疗效,能改善临床症状和脑血流动力学指标,降低血清炎性因子水平,安全性较高,具有一定的临床推广应用价值。

Objective To study the effect of Compound Haishe Capsules combined with Huperzine A Tablets in treatment of Alzheimer’s disease. Methods Patients(126 cases) with Alzheimer’s disease in Wenchang People’s Hospital from January 2016 to January 2019 were randomly divided into control and treatment groups, and each group had 63 cases. Patients in the control group were po administered with Huperzine A Tablets, 2 tablets/time, twice daily. Patients in the treatment group were po administered with Compound Haishe Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and ADL scores, MMSE scores, CDR scores, the MFV and the PI of BA and MCA, and the serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.37% and 93.65%, respectively, and there was difference between two groups(P < 0.05). After treatment, the MMSE scores and the ADL scores in two groups were significantly increased, but the CDR scores in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the MFV of BA and MCA in two groups were significantly increased, but the PI of BA and MCA in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the the MFV and the PI of BA and MCA in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of IL-6, hs-CRP, and MDA in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Compound Haishe Capsules combined with Huperzine A Tablets has clinical curative effect in treatment of Alzheimer’s disease, can improve clinical symptoms and cerebral hemodynamic indexes, and reduce the serum levels of inflammatory factors, with good safety, which has a certain clinical application value.